Putting a spotlight on critical unmet healthcare needs

D&D Pharmatech funds the development of innovative therapeutic and diagnostic solutions to address critical unmet healthcare needs. D&D subsidiary Theraly Fibrosis is developin a novel treatment for chronic pancreatitis and other fibrosis, recently granted an orphan drug designation from the US FDA.

Go to the profile of D&D Pharmatech
Nov 19, 2019
0
0
Page of
Go to the profile of D&D Pharmatech

D&D Pharmatech

D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. This corporate structure creates a unique opportunity to accelerate translation of cutting-edge research into lifesaving therapeutic products for patients. The company’s product pipeline focuses on a range of indications including neurodegenerative and fibrotic diseases. D&D Pharmatech is the parent company of U.S.-based Neuraly Inc., Theraly Fibrosis Inc., and Precision Molecular Inc.

No comments yet.